About EAST INDIA PHARMACEUTICAL WORKS LIMITED Unlisted Shares
East India Pharmaceutical Works Limited (EIPW) is one of the oldest pharmaceutical companies in India, Founded on 27 April 1936, it is involved in the Manufacturing of Healthcare Products. It is registered at the registrar of companies in Kolkata. The authorized equity share capital of the company is Rs. 10,00,00,000 and the paid-up capital is Rs. 6,67,45,180.
The Company has over 87 years of experience and has a focused “people-centric approach” which enabled it to evolve with ever-changing healthcare needs and it offers high-quality advanced medicines for modern-day health complexities.
Along with its high-quality products and experienced medical and research team, backed by the most advanced and precise equipment and infrastructure, the company ensures international quality standards at every stage of production. East India Pharmaceutical is focused to use cost-effective processes to produce high-volume formulations. The company has achieved GMP, WHO-GMP, and GLP certifications.
INCORPORATION DETAILS
|
CIN |
U24231WB1936PLC008598 |
|
Registration Date |
27 April 1936 |
|
Company Name |
EAST INDIA PHARMACEUTICAL WORKS LIMITED |
|
Email Address |
dcs@eastindiapharma.org |
|
Category/Sub-category of the Company |
Company Limited by Shares/Non-Government Company |
|
Class of Company |
Public |
|
Registration Number |
8598 |
|
Banker |
Punjab National Bank |
|
Address of the Registered office & contact details |
6, Nandalal Bose Sarani, Kolkata 700 071 |
|
Statutory Auditors |
M/s APS Associates Chartered Accountants |
|
Cost Auditors |
M/s DGM & Associates Cost Accountants |
|
Company Secretary |
Ms. Jayeeta Sarkar |
|
Registrar and Share Transfer Agent |
C B Management Services (P) Ltd. P-22, Bondel Road, Kolkata - 700 019 |
|
Listing Status |
Unlisted |
PARTICULAR OF SUBSIDIARY COMPANIES
|
Name of the Company |
Subsidiary |
% of shares held |
|
Qasar Healthcare Private Limited |
Subsidiary |
99.5% |
BOARD OF DIRECTORS
Mr. Debarshi Duttagupta (Managing Director)
Mrs. Satarupa Mukherjee (Executive Director)
Prof. (Dr.) Ranabir Mukherjee
Mr. Probir Roy (Chairman)
Mr. Dilip Samadar (Member)
Prof. (Dr.) Suman Kumar Mukerjee
Mr. Sukamal Chandra Basu (Member)
Mr. Chiraranjan Addy
Prof. (Dr.) Himadri Sengupta
Dr. Abhijit Banerjee
Dr.Tapas Raychaudhury
Mrs. Indrani Sen
Mrs. Sanghamitra Duttagupta
Mrs. Trishna Guha
Principal Business Activities of the Company
|
Name & Description of main products/services |
NIC Code of the Product /service |
% to total turnover of the company |
|
Manufacture of bulk drugs, Manufacture & sale of formulations & Trading Activities |
210 |
100% |
SHAREHOLDING PATTERN (As of 31-03-2021)
|
S. No. |
Shareholder’s Category |
No. of Shares |
% of total Shares of the company |
|
1 |
PROMOTERS |
20,09,361 |
30.11% |
|
2 |
PUBLIC |
46,65,497 |
69.89% |
|
|
Total |
66,74,858 |
100% |
Industry Outlook
The company is one of the oldest pharmaceutical companies in India that develops, manufactures, and markets high-quality medicines. The company has two manufacturing plants, one in Durgapur and one in Kolkata, with cutting-edge production facilities. The rapid spread of the COVID-19 pandemic had a significant impact on global economic activity. In India, like other countries around the world, has been severely impacted. IMF forecasts a 4.5 percent contraction in India for 2021. Finance Minister announced an additional outlay of Rs. 1,97,000 crore (USD 26,578.3 million) for the pharmaceutical Production Linked Incentive (PLI) scheme.
FY 2020-2021 Highlights of Company
PROFIT & LOSS STATEMENT OF EAST INDIA PHARMACEUTICAL WORKS LIMITED (In Rs.)
(As of 31-03-2019 to 31-03-2021)
|
Particular |
2021 |
2020 |
2019 |
|
Revenue |
|||
|
Revenue from Operations |
1,72,67,84,326 |
1,58,39,11,504 |
1,61,28,72,834 |
|
Other Income |
1,80,260 |
15,71,901 |
12,35,696 |
|
Total Revenue |
1,72,69,64,586 |
1,58,54,83,405 |
1,61,41,08,530 |
|
Expenses |
|||
|
Cost of materials consumed |
49,96,34,132 |
46,57,72,212 |
45,62,48,199 |
|
Purchases of Traded Goods |
1,71,87,443 |
1,77,56,384 |
1,26,64,335 |
|
Finished goods, Work-in-Progress, and Traded Goods |
2,83,85,036 |
(4,58,18,931) |
(1,19,97,983 |
|
Employee Benefits Expenses |
63,98,08,743 |
59,20,38,256 |
54,00,90,712 |
|
Finance Costs |
5,05,30,470 |
5,55,92,371 |
5,69,63,781 |
|
Depreciation and Amortisation Expenses |
2,60,54,248 |
3,03,52,719 |
1,63,96,508 |
|
Research and Development Expenses |
1,35,43,417 |
1,36,07,606 |
1,18,54,490 |
|
Other Expenses |
39,67,63,227 |
42,54,57,542 |
51,58,75,286 |
|
Total Expenses |
1,67,19,06,716 |
1,55,47,58,159 |
1,59,80,95,328 |
|
Profit / (Loss) Before Tax |
5,50,57,870 |
3,07,25,246 |
1,60,13,202 |
|
Tax Expenses |
|||
|
Current tax |
2,50,00,000 |
1,00,00,000 |
45,00,000 |
|
Deferred tax |
(65,97,317) |
(45,64,268) |
(26,25,388) |
|
Tax Adj. of earlier Years |
51,99,659 |
52,41,291 |
14,72,927 |
|
Total |
2,36,02,342 |
1,06,77,023 |
33,47,539 |
|
Profit / (Loss) For the Year |
3,14,55,528 |
2,00,48,223 |
1,26,65,663 |
|
Earnings Per Equity Shares |
|||
|
Earnings Per Equity Shares (Basic) |
4.71 |
3.00 |
1.90 |
|
Earnings Per Equity Shares (Diluted) |
4.71 |
3.00 |
1.90 |
BALANCE SHEET OF EAST INDIA PHARMACEUTICAL WORKS LIMITED (In Rs.) (As of 31-03-2019 to 31-03-2021)
|
PARTICULARS |
2021 |
2020 |
2019 |
|
EQUITY AND LIABILITIES: |
|||
|
Share Capital |
6,67,45,179 |
6,67,45,179 |
6,67,45,179 |
|
Reserves and Surplus |
40,56,16,066 |
38,08,35,247 |
36,48,10,162 |
|
Minority Interest |
(45,888) |
(45,738) |
(45,635) |
|
Non-Current Liabilities: |
|||
|
Long-Term Borrowings |
4,23,36,281 |
32,67,440 |
12,40,426 |
|
Long-Term Provisions |
8,14,91,000 |
6,43,20,000 |
5,51,46,000 |
|
Current Liabilities: |
|||
|
Short-Term Borrowings |
32,19,00,853 |
35,31,62,674 |
31,40,23,439 |
|
Trade Payables |
34,39,64,616 |
34,94,48,075 |
30,64,48,374 |
|
Other Current Liabilities |
19,62,03,669 |
17,44,73,972 |
17,31,13,522 |
|
Short-Term Provisions |
3,35,77,000 |
1,65,09,000 |
90,90,000 |
|
TOTAL LIABILITIES |
1,49,17,88,776 |
1,40,87,15,849 |
1,29,05,71,467 |
|
ASSETS |
|||
|
Non-Current Assets |
|||
|
Fixed Assets |
|||
|
Tangible Assets |
15,41,09,850 |
17,06,81,797 |
9,63,38,731 |
|
Intangible Assets |
7,82,364 |
8,26,060 |
9,34,088 |
|
Capital work-in-progress |
37,32,327 |
66,27,594 |
9,78,80,503 |
|
Deferred Tax Assets (Net) |
4,89,77,722 |
4,23,80,405 |
3,78,16,137 |
|
Long-Term Loans and Advances |
71,16,873 |
1,00,86,375 |
90,98,712 |
|
Current Assets |
|||
|
Inventories |
34,94,30,415 |
37,83,84,071 |
26,87,61,911 |
|
Trade Receivables |
70,98,01,337 |
57,00,98,674 |
53,42,38,157 |
|
Cash and Cash Equivalents |
15,67,73,363 |
12,68,82,571 |
16,89,35,815 |
|
Short-Term Loans and Advances |
6,10,64,525 |
10,07,48,302 |
7,45,67,413 |
|
Other Current Assets |
NIL |
20,00,000 |
20,00,000 |
|
TOTAL ASSETS |
149,17,88,776 |
140,87,15,849 |
129,05,71,467 |
DIVIDEND AND RETAINED EARNINGS (As of 31-03-2019 to 31-03-2021)
|
Particulars |
2021 |
2020 |
2019 |
|
Dividend (in Rs.) |
1.25 |
1.00 |
0.50 |
|
Retained Earnings |
248.11 |
160.46 |
126.77 |
PERFORMANCE OF THE COMPANY
Revenue from operation increased from Rs. 1,58,39,11,504 in FY 2020 to Rs. 1,72,67,84,326 in FY 2021, showing a growth of 9.03% as compared to the previous financial year.
Finance Cost has decreased from Rs. 5,55,92,371 in FY 2020 to Rs. 5,05,30,470 in FY 2021, showing a decline of 9.11% as compared to the previous financial year.
In FY 2021, Company’s Net profit stood at Rs. 3,14,55,528 as against to net profit of Rs. 2,00,48,223 in FY 2020 showing a growth of 56.9% as compared to the previous financial year.
The Current Ratio of the company as of 31st March 2021 was 1.43.
The debt-to-equity ratio of the company as of 31st March 2021 was 3.16.
The Company paid a dividend of Rs. 1.25 in the financial year 2020-2021
